• Journals Master List
  • DOAJ
  • 数据库logo
  • EuroPub
Zhao Xue, Yu Che, Wang Rong. Clinicopathological features of 71 patients with amyloidosis nephropathy[J]. Journal of Clinical Nephrology, 2021, 21(6): 455-462. DOI: 10.3969/j.issn.1671-2390.y20-232
Citation: Zhao Xue, Yu Che, Wang Rong. Clinicopathological features of 71 patients with amyloidosis nephropathy[J]. Journal of Clinical Nephrology, 2021, 21(6): 455-462. DOI: 10.3969/j.issn.1671-2390.y20-232

Clinicopathological features of 71 patients with amyloidosis nephropathy

Funds: 

National Natural Science Foundation of China(81770723)

More Information
  • Received Date: October 25, 2020
  • Available Online: May 11, 2023
  • Published Date: June 27, 2021
  • Objective To explore the clinicopathological features of patients with amyloidosis nephropathy to provide more rationales for clinical diagnosis and treatment.Methods From December 1997 to December 2019,clinicopathological data were retrospectively reviewed for 71 patients with amyloidosis diagnosed by renal biopsy.Results The mean age was(57.2±9.9)years,71.8% were aged 50 to 69 years and male-to-female ratio was 1.7∶1.The age and hemoglobin levels of males were higher than those of females.And the differences were statistically significant(P<0.05).Hemoglobin and serum calcium in patients with higher serum creatinine(Scr)were significantly lower(P<0.05)while urea nitrogen,cystatin C,β2-microglobulin and uric acid were significantly higher than those with normal creatinine(P<0.05).In a declining order,amyloid was deposited in glomerular mesangial area(96.2%),capillary wall(28.3%),interstitial small vessel wall(47.2%),tubules(15.1%),renal interstitium(5.7%)and subendothelium(1.9%).In group of higher Scr,the rates of amyloid deposition were both higher in glomeruli(P=0.032)and tubular atrophy >10%(P=0.024).However,no significant difference existed in clinicopathological parameters between patients with nephrotic-range proteinuria and non-nephrotic-range proteinuria.Conclusion Amyloidosis nephropathy occurs predominantly in middle-aged and elderly males.Glomerular damage is common in patients with amyloidosis nephropathy.And the degree of glomerular amyloidosis in renal tissue is associated with renal insufficiency rather than the level of urinary protein.
  • [1]
    Jazbeh S,Said A,Haddad RY,et al.Renal amyloidosis[J].Disease-a-month,2014,60(10):489-493.DOI: 10.1016/j.disamonth.2014.08.003.
    [2]
    Ryšavá R.AL amyloidosis:advances in diagnostics and treatment[J].Nephrol Dial Trans,2019,34(9):1460-1466.DOI: 10.1093/ndt/gfy291.
    [3]
    Nienhuis HL,Bijzet J,Hazenberg BP.The prevalence and management of systemic amyloidosis in western countries[J].Kidney Dis(Basel),2016,2(1):10-19.DOI: 10.1159/000444206.
    [4]
    Benson MD,Buxbaum JN,Eisenberg DS,et al.Amyloid nomenclature 2018:recommendations by the International Society of Amyloidosis(ISA)nomenclature committee[J].Amyloid,2018,25(4):215-219.DOI: 10.1080/13506129.2018.1549825.
    [5]
    Kastritis E,Gavriatopoulou M,Roussou M,et al.Renal outcomes in patients with AL amyloidosis:Prognostic factors,renal response and the impact of therapy[J].Am J Hematol,2017,92(7):632-639.DOI: 10.1002/ajh.24738.
    [6]
    Kellum JA,Lameire N,KDIGO AKI Guideline Work Group.Diagnosis,evaluation,and management of acute kidney injury:a KDIGO summary(Part 1)[J].Crit Care,2013,17(1):204.DOI: 10.1186/cc11454.
    [7]
    Levey AS,Eckardt KU,Tsukamoto Y,et al.Definition and classification of chronic kidney disease:a position statement from Kidney Disease:Improving Global Outcomes(KDIGO)[J].Kidney Int,2005,67(6):2089-2100.DOI: 10.1111/j.1523-1755.2005.00365.x.
    [8]
    Atkin C,Richter A,Sapey E.What is the significance of monoclonal gammopathy of undetermined significance?[J].Clin Med(Lond),2018,18(5):391-396.DOI: 10.7861/clinmedicine.18-5-391.
    [9]
    Leung N,Bridoux F,Hutchison CA,et al.Monoclonal gammopathy of renal significance:when MGUS is no longer undetermined or insignificant[J].Blood,2012,120(22):4292-4295.DOI: 10.1182/blood-2012-07-445304.
    [10]
    Said SM,Sethi S,Valeri AM,et al.Renal amyloidosis:origin and clinicopathologic correlations of 474 recent cases[J].Clin J Am Soc Nephrol,2013,8(9):1515-1523.DOI: 10.2215/CJN.10491012.
    [11]
    Panizo N,Rivera F,López-Gómez JM,et al.Decreasing incidence of AA amyloidosis in Spain[J].Eur J Clin Invest,2013,43(12):1371.DOI: 10.1111/eci.12156.
    [12]
    Kyle RA,Gertz MA.Primary systemic amyloidosis:clinical and laboratory features in 474 cases[J].Semin Hematol,1995,32(1):45-59.
    [13]
    Yao Y,Wang SX,Zhang YK,et al.A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis[J].Nephrol Dial Trans,2013,28(3):689-697.DOI: 10.1093/ndt/gfs501.
    [14]
    向流霞,袁曙光,张新民,等.76例淀粉样变性肾损害的临床病理特点[J].临床与病理杂志,2018,38(8):1675-1681.DOI: 10.3978/j.issn.2095-6959.2018.08.013.

    Xiang LX,Yuan SG,Zhang XM,et al.Clinicopathological features of renal impairment in 76 cases with amyloidosis[J].Int J Pathol Clin Med,2018,38(8):1675-1681.DOI: 10.3978/j.issn.2095-6959.2018.08.013.
    [15]
    姚英,章友康,王素霞.AL型肾淀粉样变的临床病理特点和治疗进展[J].中华临床医师杂志(电子版),2012,6(15):4180-4181.DOI: 10.3877/cma.j.issn.1674-0785.2012.15.005.

    Yao Y,Zhang YK,Wang SX.Clinicopathological characteristics and treatment progress of AL renal amyloidosis[J].Chin J Clin Electron Ed,2012,6(15):4180-4181.DOI: 10.3877/cma.j.issn.1674-0785.2012.15.005.
    [16]
    Ji C,Su Y,Zhang C,et al.Reference intervals for hemoglobin and age-and gender-related trends in the population of southwest China[J].Clin Lab,2015,61(12):1831-1836.DOI: 10.7754/clin.lab.2015.150423.
    [17]
    Gertz MA,Comenzo R,Falk RH,et al.Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis(AL):a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis,Tours,France,18-22 April 2004[J].Am J Hematol,2005,79(4):319-328.DOI: 10.1002/ajh.20381.
    [18]
    姚英,王素霞,章友康,等.国人190例免疫球蛋白轻链型淀粉样变性病临床与病理的相关性分析[J].中华临床医师杂志(电子版),2013,7(14):6344-6348.DOI: 10.3969/cma.j.issn.1674-0785.2013.14.031.

    Yao Y,Wang SX,Zhang YK,et al.Associations between pathological features and clinical manifestations of immunoglobulin light-chain renal amyloidosis[J].Chin J Clin Electron Ed,2013,7(14):6344-6348.DOI: 10.3969/cma.j.issn.1674-0785.2013.14.031.
    [19]
    Itabashi M,Takei T,Tsukada M,et al.Association between clinical characteristics and AL amyloid deposition in the kidney[J].Heart Vessels,2010,25(6):543-548.DOI: 10.1007/s00380-010-0019-y.
    [20]
    陆怡敏.87例肾淀粉样变的临床病理研究[D].上海:上海交通大学,2008:1-55.

    Lu YM.Clinico-pathological Study of 87 patients of renal amyloidosis[D].Shanghai:Shanghai Jiaotong University,2008:1-55.
    [21]
    Klomjit N,Leung N,Fervenza F,et al.Rate and predictors of finding monoclonal gammopathy of renal significance(MGRS)lesions on kidney biopsy in patients with monoclonal gammopathy[J].J Am Soc Nephrol,2020,31(10):2400-2411.DOI: 10.1681/ASN.2020010054.
    [22]
    Kyle RA,Therneau TM,Rajkumar SV,et al.A long-term study of prognosis in monoclonal gammopathy of undetermined significance[J].N Engl J Med,2002,346(8):564-569.DOI: 10.1056/NEJMoa01133202.
    [23]
    Nasr SH,Satoskar A,Markowitz GS,et al.Proliferative glomerulonephritis with monoclonal IgG deposits[J].J Am Soc Nephrol,2009,20(9):2055-2064.DOI: 10.1681/ASN.2009010110.
    [24]
    Andeen NK,Troxell ML,Riazy M,et al.Fibrillary glomerulonephritis:clinicopathologic features and atypical cases from a multi-institutional cohort[J].Clin J Am Soc Nephrol,2019,14(12):1741-1750.DOI: 10.2215/cjn.03870319.
    [25]
    Hetzel GR,Uhlig K,Mondry A,et al.AL-amyloidosis of the kidney initially presenting as minimal change glomerulonephritis[J].Am J Kid Dis,2000,36(3):630-635.DOI: 10.1053/ajkd.2000.16205.
    [26]
    Sayed RH,Gilbertson JA,Hutt DF,et al.Misdiagnosing renal amyloidosis as minimal change disease[J].Nephrol Dial Trans,2014,29(11):2120-2126.DOI: 10.1093/ndt/gfu242.
    [27]
    Tsuji K,Arai H,Furusu A,et al.A case of membranoproliferative glomerulonephritis and AA amyloidosis complicated with pulmonary nontuberculous mycobacterial infection[J].CEN Case Rep,2015,4(1):24-30.DOI: 10.1007/s13730-014-0134-1.
    [28]
    Rosenstock JL,Markowitz GS.Fibrillary glomerulonephritis:an update[J].Kidney Int Rep,2019,4(7):917-922.DOI: 10.1016/j.ekir.2019.04.013.
    [29]
    Schwartz MM,Korbet SM,Lewis EJ.Immunotactoid glomerulopathy[J].J Am Soc Nephrol,2002,13(5):1390-1397.DOI: 10.1097/01.asn.0000013397.06964.19.
    [30]
    Chen TT,Achan A,Li K,et al.Collagenofibrotic glomerulopathy[J].Nephrology(Carlton),2018,23(6):601-602.DOI: 10.1111/nep.13107.
    [31]
    Wang Q,Jiang F,Xu GS.The pathogenesis of renal injury and treatment in light chain deposition disease[J].J Transl Med,2019,17(1):387.DOI: 10.1186/s12967-019-02147-4.
    [32]
    Nasr SH,Fogo AB.New developments in the diagnosis of fibrillary glomerulonephritis[J].Kidney Int,2019,96(3):581-592.DOI: 10.1016/j.kint.2019.03.021.
    [33]
    Nasr SH,Vrana JA,Dasari S,et al.DNAJB9 is a specific immunohistochemical marker for fibrillary glomerulonephritis[J].Kid Int Rep,2018,3(1):56-64.DOI: 10.1016/j.ekir.2017.07.017.
  • Related Articles

    [1]Hu Xiao-qin, Long Qing, Du Ran, Tian Hai-rong, Xiong Jiu-hong. Prognostic value of serum levels of miR-155 and Smad5 in hemodialysis patients with acute renal failure[J]. Journal of Clinical Nephrology, 2023, 23(11): 903-909. DOI: 10.3969/j.issn.1671-2390.2023.11.004
    [2]Bao Shu-min, Zhang Guo-juan, Li Bing-han, Liu Ning, Zheng Jie. Brucellosis with renal failure, abdominal pain, gastrointestinal hemorrhage and recurrent angina: one case report[J]. Journal of Clinical Nephrology, 2023, 23(8): 702-705. DOI: 10.3969/j.issn.1671-2390.2023.08.016
    [3]Hu yang-yang, Ke Lin, Li Yue-qiang, Han Min, Deng Yuan-jun. Clinicopathological features of light chain deposition disease with renal injury[J]. Journal of Clinical Nephrology, 2023, 23(8): 670-674. DOI: 10.3969/j.issn.1671-2390.2023.08.009
    [4]Ai Yuan-yuan, Bao Si-zeng, Wang Yu, Bian Xue-yan. One case report of ANCA-associated vasculitis with positive antibody for Hanta virus[J]. Journal of Clinical Nephrology, 2023, 23(1): 86-88. DOI: 10.3969/j.issn.1671-2390.2023.01.016
    [5]Zhou Ji, Shen Li-min. Relationship between serum osteopontin concentration and progression of diabetic nephropathy and renal function[J]. Journal of Clinical Nephrology, 2022, 22(8): 653-658. DOI: 10.3969/j.issn.1671-2390.2022.08.006
    [6]Chen Hong-yu, Li Fang-ming, Zeng Li-mei. Curative effect of hemoperfusion plus hemodialysis and hemodiafiltration in the treatment of elderly chronic renal insufficiency[J]. Journal of Clinical Nephrology, 2021, 21(7): 529-534. DOI: 10.3969/j.issn.1671-2390.m20-196
    [7]XU Jing, XIE Wei-ji, ZHANG Yi-min. One case of acute renal injury resulting from adrenal insufficiency[J]. Journal of Clinical Nephrology, 2020, 20(3): 256-259. DOI: 10.3969/j.issn.1671-2390.2020.03.017
    [8]LIANG Qiao-jing, ZHANG Guo-juan, HUANG Wen. Meta-analysis comparing apixaban versus warfarin anticoagulation therapies for patients with severe renal insufficiency[J]. Journal of Clinical Nephrology, 2019, 19(11): 813-818. DOI: 10.3969/j.issn.1671-2390.2019.11.005
    [9]HU Ai-xia, LIU Tao. Effect of renal interstitial vascular lesions on clinical pathological features and outcomes of lupus nephritis[J]. Journal of Clinical Nephrology, 2019, 19(10): 765-768,777. DOI: 10.3969/j.issn.1671-2390.2019.10.010
    [10]CHEN Jing, LIAO Yun-juan, JIANG Hong-ying, LI Ji-sai, LI Luo-hua, LI Jing. A mono-center clinical study on clinical pathological features and prognosis of adult idiopathic membranous nephropathy[J]. Journal of Clinical Nephrology, 2019, 19(4): 245-250. DOI: 10.3969/j.issn.1671-2390.2019.04.004
  • Cited by

    Periodical cited type(2)

    1. 耿倩,蔡艳,周竹,范志立. AL型肾淀粉样变一例报道. 云南医药. 2023(02): 116-118 .
    2. 陈巧玲,林婉君,廖永根,叶秋萍,刘丽芳,魏立新. 单中心成人特发性膜性肾病的临床病理特点和预后分析. 中国医学创新. 2022(24): 59-65 .

    Other cited types(0)

Catalog

    Article views (313) PDF downloads (299) Cited by(2)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return